{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:06:58Z","timestamp":1782950818540,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p><jats:italic>Mycoplasma genitalium<\/jats:italic> (MG) is a sexually transmitted bacterium of public health importance, associated with genitourinary disorders, and adverse reproductive and perinatal outcomes. Global data on MG prevalence and antimicrobial resistance (AMR) are primarily available from high-income countries, whereas there is a dearth of information from resource-constrained settings including sub-Saharan Africa. Furthermore, international data on MG rates and AMR in the antenatal population are scarce. Understanding MG prevalence and AMR patterns is crucial for developing effective public health strategies and treatment guidelines. The aim of this study was to investigate the prevalence and epidemiology of MG and the presence of macrolide resistance-associated mutations (MRAMs) among pregnant women attending antenatal care facilities in Zambia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional study was conducted at four antenatal care facilities in Nchelenge, Zambia, among 1,021 pregnant women. Vaginal swabs were collected and tested using the Aptima <jats:italic>Mycoplasma genitalium<\/jats:italic> assay, Aptima Combo 2 assay and Aptima <jats:italic>Trichomonas vaginalis<\/jats:italic> assay on the Panther System (Hologic). MG-positive samples were further analyzed for MRAMs using the ResistancePlus\u2122 MG assay (SpeeDx).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of MG was 12.6% (127 of 1,005 valid samples) among the pregnant women. Only 12 MG-positive women (9.4%) had symptoms of a genitourinary infection, which was similar to the frequency of genitourinary symptoms among MG-negative women (6.1%). The rates of <jats:italic>Chlamydia trachomatis, Neisseria gonorrhoeae, T. vaginalis<\/jats:italic>, and HIV seropositivity were 7.4, 8.3, 23.0, and 8.6%, respectively. MG infection was significantly associated with the presence of all other tested sexually transmitted infections and HIV seropositivity: the detection rates of <jats:italic>C. trachomatis, N. gonorrhoeae, T. vaginalis<\/jats:italic>, and HIV seropositivity were significantly higher in MG-positive than in MG-negative women (15.1% vs. 6.2, 15.0% vs. 7.5, 32.3% vs. 22.0, and 14.3% vs. 7.5%, respectively). The ResistancePlus\u2122 MG assay detected MG in 66.1% (84\/127) of samples positive by the Aptima <jats:italic>M. genitalium<\/jats:italic> assay, however, no MRAMs were detected in the 23S rRNA gene for any of these 84 samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study emphasizes the high prevalence of MG among pregnant women in Zambia, but also lack of MRAMs in MG. These findings suggest that azithromycin remains an efficacious treatment option for MG in this population. Nevertheless, continuous surveillance and judicious macrolide use to maintain treatment efficacy are imperative. Further research and sustained monitoring of MG are essential to inform public health strategies and clinical guidelines in Zambia and similar settings worldwide.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1576376","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:11:15Z","timestamp":1746763875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and epidemiology of Mycoplasma genitalium and the absence of macrolide resistance in M. genitalium among pregnant women attending antenatal care in Zambia"],"prefix":"10.3389","volume":"13","author":[{"given":"Daniel","family":"Schr\u00f6der","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumire","family":"Sorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Shipitsyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enesia Banda","family":"Chaponda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Golparian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Chikwanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Mwewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"Mulenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Chaponda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsui","family":"Mitsuaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mirandola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Blondeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Toskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Matthew","family":"Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","article-title":"Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis","volume":"94","author":"Baumann","year":"2018","journal-title":"Sex Transm Infect"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.lanmic.2024.101047","article-title":"Evolving patterns of macrolide and fluoroquinolone resistance in Mycoplasma genitalium: an updated systematic review and meta-analysis","author":"Chua","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","article-title":"2021 European guideline on the management of Mycoplasma genitalium infections","volume":"36","author":"Jensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"ciae295","DOI":"10.1093\/CID\/CIAE295","article-title":"Systematic review and meta-analysis of the association between Mycoplasma genitalium and pelvic inflammatory disease (PID)","author":"Htaik","year":"2024","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/cid\/civ312","article-title":"Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis","volume":"61","author":"Lis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/SEXTRANS-2021-055352","article-title":"Adverse pregnancy and perinatal outcomes associated with Mycoplasma genitalium: systematic review and meta-analysis","volume":"98","author":"Frenzer","year":"2022","journal-title":"Sex Transm Infect"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/PHAR.1649","article-title":"A review of antibiotic use in pregnancy","volume":"35","author":"Bookstaver","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14737159.2020.1842198","article-title":"A profile of the FDA-approved and CE\/IVD-marked Aptima Mycoplasma genitalium assay (Hologic) and key priorities in the management of M. genitalium infections","volume":"20","author":"Shipitsyna","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cmi.2017.09.006","article-title":"Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016","volume":"24","author":"Unemo","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1186\/s12879-025-10698-9","article-title":"Diagnostic accuracy of an antigen-based point-of-care test versus nucleic acid amplification testing for genital trichomoniasis among pregnant women attending antenatal care facilities in Zambia","volume":"24","author":"Sorano","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1130762","DOI":"10.3389\/fmicb.2023.1130762","article-title":"Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru","volume":"14","author":"Shipitsyna","year":"2023","journal-title":"Front Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"50475","DOI":"10.1136\/bmjopen-2021-050475","article-title":"Retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern USA","volume":"11","author":"Stafford","year":"2021","journal-title":"BMJ Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijgo.15529","article-title":"Sexually transmitted infections in pregnancy and adverse pregnancy outcomes: a retrospective cohort study","volume":"166","author":"Govender","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4102\/SAJID.V36I1.209","article-title":"Lack of resistance to macrolides in Mycoplasma genitalium detected in South African pregnant women","volume":"36","author":"Naicker","year":"2021","journal-title":"South Afr J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/09564624221129412","article-title":"Low prevalence of macrolide resistance in Mycoplasma genitalium infections in a cohort of pregnant women living with human immunodeficiency virus","volume":"33","author":"Ngobese","year":"2022","journal-title":"Int J STD AIDS"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3201\/EID2703.201783","article-title":"Mycoplasma genitalium and other reproductive tract infections in pregnant women, Papua New Guinea, 2015-2017","volume":"27","author":"Scoullar","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/SEXTRANS-2019-054255","article-title":"Prevalence and incidence of Mycoplasma genitalium in a cohort of HIV-infected and HIV-uninfected pregnant women in Cape Town, South Africa","volume":"96","author":"Smullin","year":"2020","journal-title":"Sex Transm Infect"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/sextrans-2022-055552","article-title":"Mycoplasma genitalium macrolide and fluoroquinolone resistance in pregnant women in Papua New Guinea","volume":"99","author":"Jonduo","year":"2022","journal-title":"Sex Transm Infect"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jia2.25343","article-title":"Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward","volume":"22","author":"Wi","year":"2019","journal-title":"J Int AIDS Soc"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1576376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:11:15Z","timestamp":1746763875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1576376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":21,"alternative-id":["10.3389\/fpubh.2025.1576376"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1576376","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1576376"}}